Research programme: human therapeutic antibodies - Medarex/Pfizer
Latest Information Update: 03 Sep 2009
At a glance
- Originator Medarex; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Autoimmune disorders; Bacterial infections; Cancer; Inflammation; Viral infections